The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5) Barton, D. L. , Atherton, P. J. , Bauer, B. A. , Moore, D. F. Jr ... - - J Support Oncol - 2011 Manuscript - Primary - Primary - Symptom Inter - N01C5
Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9 Barton, D. L. , Lavasseur, B. I. , Sloan, J. A. , Stawis, A. N. ... - - J. Clin. Oncol. - 2010 Manuscript - Primary - Primary - Symptom Inter - N05C9
A phase III trial evaluating three doses of citalopram for hot flashes: NCCTG trial N05C9 Barton, D. L. , Lavasseur, B. , Sloan, J. A. , Stella, P. J. ... - - J. Clin. Oncol. - 2008 Abstract - Primary - Primary - Symptom Inter - N05C9
Phase III evaluation of American ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N07C2 Barton, D. L. , Liu, H. , Dakhil, S. R. , Linquist, B. M. ... - - J. Clin. Oncol. - 2012 Abstract - Primary - Primary - Symptom Inter - N07C2
Wisconsin ginseng (Panax quinquefolius) to improve cancer-related fatigue: A randomized, double-blind trial, N07C2 Barton, D. L. , Liu, H. , Dakhil, S. R. , Linquist, B. , Sloan, J. A. ... - - J. Natl. Cancer Inst. - 2013 Manuscript - Primary - Primary - Symptom Inter - N07C2
Long-acting methylphenidate for cancer-related fatigue: NCCTG trial N05C7 Barton, D. L. , Moraska, A. R. , Sood, A. , Sloan, J. A. , Suh, J. J. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - Symptom Inter - N05C7
Can gabapentin improve control of delayed nausea and vomiting (N/V)? A phase III placebo controlled trial, N08C3 (Alliance) Barton, D. L. , Sloan, J. A. , Novotny, P. J. , Fuloria, J. ... - - Support Care Cancer - 2013 Abstract - Primary - Primary - Symptom Inter - N08C3
Does gabapentin prevent delayed chemotherapy-induced nausea and vomiting (N/V)? Results of a randomized placebo controlled trial, NCCTG N08C3 (Alliance) Barton, D. L. , Sloan, J. A. , Novotny, P. J. , Fuloria, J. ... - - J. Clin. Oncol. - 2013 Abstract - Primary - Primary - Symptom Inter - N08C3
Patient satisfaction with participation in phase II/III NCCTG clinical trials: Was it worth it? (N0392) Chauhan, C. , Atherton, P. J. , Satele, D. , Dueck, A. C. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Primary - Primary - Health Outcome - NCCTG-N0392
Validity and reliability of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Dueck, A. C. , Mendoza, T. R. , Mitchell, S. A. , Reeve, B. B. ... - - J. Clin. Oncol. - 2012 Abstract - No-Endpoint - Primary - Health Outcome - Comprehensive
Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance) Dueck, A. C. , Singh, J. , Atherton, P. , Liu, H. , Novotny, P. ... - - Osteoporos Int - 2015 Manuscript - Secondary-not-in-original - Primary - Health Outcome - N02C1 , N03CC
Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511) Freedman, Rachel A. , Seisler, D. K. , Foster, J. C. , Sloan, J. A. ... - - Breast Cancer Res. Treat. - 2017 Manuscript - Primary - Primary - Older Adult - A151511 , CALGB-40101 , CALGB-49907 , CALGB-9344 , CALGB-9741
Assessing the clinical significance of real-time Quality of Life (QOL) data in cancer patients treated with radiation therapy Halyard, M. Y. , Tan, A. D. , Callister, M. D. , Ashman, J. B. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Secondary - Primary - Health Outcome - NCCTG-89-20-52
Comparing and validating simple measures of patient-reported peripheral neuropathy (PRPN) for NCCTG Clinical Trials: A pooled analysis of 2,440 patients (pts) Liu, H. , Tan, A. D. , Grothey, A. , Schaefer, P. L. , Buckner, J. C. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original - Primary - Symptom Inter - N0897
A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: NCCTG study N04CA Loprinzi, C. L. , Balcueva, E. P. , Liu, H. , Kottschade, L. A. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - Symptom Inter - N04CA
A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: North Central Cancer Treatment group study N04CA Loprinzi, C. L. , Balcueva, E. P. , Liu, H. , Sloan, J. A. ... - - J Support Oncol - 2011 Manuscript - Primary - Primary - Symptom Inter - N04CA
Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1 Loprinzi, C. L. , Reeves, B. N. , Dakhil, S. R. , Sloan, J. A. ... - - J. Clin. Oncol. - 2011 Manuscript - Primary - Primary - Health Outcome - N08C1
Quality of life (QOL) for patients treated with FOLFOX+/-cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) Phase III Trial N0147 Mahoney, M. R. , Sloan, J. A. , Hubbard, J. M. , Liu, H. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original - Primary - GI - N0147
Primary and Secondary Endpoint Analysis of N08C9 (Alliance)- A Phase III Randomized Trial of Sulfasalazine versus Placebo in the Prevention of Acute Radiation Enteritis Miller, R. C. , Petereit, D. G. , Sloan, J. A. , Liu, H. ... - ASCO GI - J. Clin. Oncol. - 2015 Abstract - Secondary - Primary - Symptom Inter - N08C9
Primary and Secondary Endpoint Analysis of N08C9 (Alliance)- A Phase III Randomized Trial of Sulfasalazine versus Placebo in the Prevention of Acute Radiation Enteritis Miller, R. C. , Petereit, D. G. , Sloan, J. A. , Liu, H. ... - ASTRO - INT J RADIAT BIOL - 2014 Abstract - Secondary - Primary - Symptom Inter - N08C9
N08C9 (Alliance) - A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy Miller, R. C. , Petereit, D. G. , Sloan, J. A. , Liu, H. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2013 Abstract - Primary - Primary - Symptom Inter - N08C9
Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial Moraska, A. R. , Sood, A. , Dakhil, S. R. , Sloan, J. A. , Barton, D. ... - - J. Clin. Oncol. - 2010 Manuscript - Primary - Primary - Symptom Inter - N05C7
Natural history of paclitaxel-associated acute pain syndrome (P-APS): NCCTG trial N08C1 Reeves, B. , Dakhil, S. R. , Sloan, J. A. , Kamal, A. , Wolf, S. L. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - Health Outcome - N08C1
Baseline quality of life (QOL) as a prognostic factor for overall survival (OS) in patients (Pts) with advanced stage non-small cell lung cancer (A-NSCLC): An analysis of NCCTG studies. Schild, S. E. , Qi, Y. , Tan, A. D. , Mandrekar, S. J. , Adjei, A. A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary - Primary - Respiratory - NCCTG-N0424
A patient-level pooled analysis of the prognostic significance of baseline fatigue for overall survival (OS) among 3,915 patients participating in 43 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer Center (MC) oncology clinical trials. Sloan, J. A. , Liu, H. , Sargent, D. J. , Satele, D. , Schaefer, P. L. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original - Primary - Health Outcome - Comprehensive
Was it worth it (WIWI)? patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) Phase III Trial N0147 Sloan, J. A. , Mahoney, M. R. , Sargent, D. J. , Hubbard, J. M. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary - Primary - Health Outcome - NCCTG-N0147
Calibration of Quality-Adjusted Life Years (QALYS) For Oncology Clinical Trials (OCT). Sloan, J. A. , Novotny, P. J. , Sargent, D. J. ... - ISOQOL - ISOQOL - 2010 Abstract - Secondary-not-in-original - Comprehensive - GI - NCCTG-N9741
Clinically Significant Effect Sizes for Survival and Response Endpoints Using the 1/2 Standard Deviation Rule. Sloan, J. A. , Novotny, P. J. , Sargent, D. J. , Decker, P. ... - - Qual Life Res - 2010 Abstract - Secondary-not-in-original - Primary - GI - NCCTG-N9741
Relationship between genetic markers and quality of life (QOL) in stage III colon cancer (CC) patients (pts) prior to adjuvant treatment (N0147). Sloan, J. A. , Shi, Q. , Lee, A. , Diasio, R. B. , Pavey, E. S. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original - Primary - Health Outcome - NCCTG-N0147
Individual Item Analysis of Quality of Life Assessments Related to Laparoscopic-assisted Colectomy in the COST Trial 93-46-53 (INT 0146) Stucky, C. H. , Pockaj, B. A. , Novotny, P. A. , Sloan, J. A. ... - - Ann. Surg. Oncol. - 2010 Abstract - Secondary - Primary - GI - NCCTG-1515
The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA Wolf, S. L. , Barton, D. L. , Qin, R. , Wos, E. J. , Sloan, J. A. ... - - Support Care Cancer - 2012 Manuscript - Secondary - Primary - Health Outcome - N06CA
Relationship of sensory symptoms and motor function in patients with chemotherapy-induced peripheral neuropathy (CIPN) utilizing the EORTC QLQ CIPN20: NCCTG study N06CA Wolf, S. L. , Qin, R. , Barton, D. L. , Sloan, J. A. , Liu, H. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary - Primary - Health Outcome - N06CA
